Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Other Announcement

OneSource Specialty Pharma Other Announcement

OneSource Specialty Pharma's partner, Orbicular Pharmaceutical Technologies, received tentative U.S. FDA approval for a generic version of Ozempic (Semaglutide Injection). OneSource served as the CDMO partner providing end-to-end manufacturing from its Bangalore facility. This milestone validates OneSource's specialized manufacturing capabilities for complex peptides and injectables.

Source

BSE filing, NSE: ONESOURCE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

OneSource Specialty Pharma Ltd: key numbers

Share price
₹1,577.60
Market cap
₹18,091 Cr
Revenue (annual)
₹1,422 Cr
Net profit (annual)
₹-73.80 Cr
P/E (TTM)
-11160.2×Sector 46.1×
Promoter holding
30.47%-0.01% QoQ
FII holding
19.45%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from OneSource Specialty Pharma Ltd

All →
10:07 IST BSE
Financial Results

OneSource Specialty Pharma Q2 FY27 Results: Net Profit ₹57.5 Cr, Up 447.6% YoY

OneSource Specialty Pharma Ltd reported revenue from operations of ₹516.2 Cr (+37.4% YoY) and net profit of ₹57.5 Cr (+447.6% YoY) for Q2 FY27.

Key figure
Net profit ₹57.5 Cr · +447.6% YoY

Other other announcement announcements

All →